Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 6, Issue , 2013, Pages 25-37

  Ballav, Chitrabhanu ^a   Gough, Stephen C L ^a  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

DPP 4 inhibitors; Incretin based therapies; Metformin; Sitagliptin; Type 2 diabetes

Indexed keywords

CIMETIDINE; DIGOXIN; EXENDIN 4; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS SITAGLIPTIN; MORPHINE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; BODY WEIGHT; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84883624784     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S7314     Document Type: Review

References (69)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7.
2. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1998;352(9139):1558]. Lancet. 1998;352(9131):837-853.
3. Nathan DM, Holman RR, Buse JB, et al. Medical management of hyper-glycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193-203.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6): 1364-1379.
5. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
6. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientifc review. JAMA. 2002;287:360-372.
7. Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am. 2005;34:77-98.
8. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1): 46-52.
9. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.
10. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94(6):1843-1852.
11. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, pep-tide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-835.
12. Hansen L, Deacon CF, Orskov C, Hoist JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356-5363.
13. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jøgensen PH, Hoist JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab. 2000; 278(6):E1010-E1018.
14. Deacon CF, Pridal L, Klarskov L, Olesen M, Hoist JJ. Glucagon-like peptide 1 undergoes differential tissue-specifc metabolism in the anesthetized pig. Am J Physiol. 1996;2713:E458-E464.
15. Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes Obes Metab. 2008;10(6):1463-2326.
16. Nauck MA, Kleine N, Orskov C, Hoist JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-744.
17. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93(10):3703-3716.
18. Legakis IN, Tzioras C, Phenekos C. Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care. 2003;26(1):252.
19. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3853-3860.
20. Lugari R, Dei Cas A, Ugolotti D, et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2001;34:150-154.
21. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57:678-687.
22. Nauck MA, Vardarli CF, Deacon CF, Hoist JJ, Meier JJ. Secretion of glu-cagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-18.
23. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethyl biguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223-228.
24. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia. 2011;54:3101-3110.
25. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin receptor substrate-2. J Clin Endocrinol Metab. 2003;88:1323-1332.
26. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on gluca-gon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489-494.
27. Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun. 2002;298(5):779-784.
28. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. Sep 2007;28(6):315-322.
29. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharma-codynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675-688.
30. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl pepti-dase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin. Clin Pharmacol Ther. 2007;81:761-767.
31. Alba M, Sheng D, Guan Y, et al. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specifc glycaemic improvement. Curr Med Res Opin. 2009;25(10):2507-2514.
32. Hermansen K, Kipnes M, Luo E, et al. Sitagliptin Study 035 Group. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733-745.
33. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;2:CD006739.
34. US Food and Drug Administration. Information for healthcare professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation-forPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764. Published 2009. Accessed Jun 26, 2013.
35. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539.
36. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies. Are the glp-1 therapies safe? Diabetes Care. 2013;36(7):2118-2125.
37. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefts by far outweigh the potential risks. Diabetes Care. 2013;36(7): 2126-2132.
38. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes. 2013;62:2178-2180.
39. European Association for the Study of Diabetes. ADA/EASD/IDF Recommendations for clinicians and people with diabetes concerning the use of incretin therapy and pancreatic disease. http://easd.org/ index.php?option=com_content&view=article&id=172. Published 2012. Accessed Jul 2013.
40. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-371.
41. European Medicines Agency. Efficib (sitagliptin/metformin) film-coated tablets: summary of product characteristics. http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/000896/ WC500021374.pdf. Accessed Jan 27, 2011.
42. Janumet TM (sitagliptin/metformin HCl) Tablets [package insert]. Whitehouse Station, NJ: Merck Pharmaceuticals, Inc; 2012.
43. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of met-formin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545-551.
44. Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycaemic agent. Am J Health Syst Pharm. 1997;54(8):893-903.
45. Glucophage (metformin) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009. http://packageinserts.bms.com/pi/pi_glucophage.pdf. Accessed Dec 7, 2011.
46. Migoya EM, Miller JL, Gutierrez M, et al. Bioequivalence of sitagliptin/ metformin fxed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. Clin Drug Investig. 2010;30(12):855-866.
47. Herman GA, Bergman A, Yi B, Kipnes M; Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl pepti-dase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22(10):1939-1947.
48. Melikian C, White TJ, Vanderplas A, Dezil CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fxed-dose combination therapy. Clin Ther. 2002;24:460-467.
49. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1c in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5:424-431.
50. Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with fxed dose combination of sitagliptin and metformin compared with met-formin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:644-652.
51. Pérez-Monteverde A, Seck T, Xu L, et al. Efficacy and safety of sitagliptin and the fxed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract. 2011;65(9): 930-938.
52. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemia control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:409-418.
53. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidylpeptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-1987.
54. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569-583.
55. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitaglip-tin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5): 442-451.
56. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor sita-gliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12): 2638-2643.
57. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537-550.
58. Karasik A, Wu M, Williams-Herman D, Meininger G. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss (Abstract 0523-P). Presented at: American Diabetes Association, 67th Sessions; Jun 22-6, 2007; Chicago, IL. http://professional.diabetes.org/ Content/Posters/2007/p0523-P.pdf.
59. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, noninferiority trial. Diabetes Obes Metab. 2007;9:194-205.
60. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Effcacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959-969.
61. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adults patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540-549.
62. Bergenstal RM, Wysham C, Macconell L, et al. DURATION-2 Study Group. Effcacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet. 2010;376:431-439.
63. American Diabetes Association. Executive summary: standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.
64. Simonson GD, Cuddihy RM, Reader D, Bergenstal RM. International Diabetes Center treatment of type 2 diabetes glucose algorithm. Diabetes Manag. 2011;1:175-189.
65. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
66. Cryer PE. Severe iatrogenic hypoglycemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2007;3:4-5.
67. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-beta: two-year effcacy and safety of initial combination therapy with nat-eglinide or glyburide plus metformin. Diabetes Care. 2005;28:2093-2209.
68. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazo-lidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309.
69. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Clin Res Rev. 2008;2:47-57.